BACKGROUND Outcomes for children with acute myeloid leukemia (AML) have improved
over the past 20 years even though the medications used for induction therapy have not …

Recent reports of recurrent mutations in childhood acute myeloid leukemia (AML) have
identified potential targets for new therapeutic strategies. Acute promyelocytic leukemia …

The prognosis of pediatric acute myeloid leukemia (AML) has improved significantly over the
past decades. However, few papers have actually illustrated this improvement, and many …

Despite substantial progress in the management of childhood acute myeloid leukemia
(AML), only about 50% of patients are cured by intensive chemotherapy. The long-term …

Pediatric acute myeloid leukemia (AML) develops from clonal expansion of hematopoietic
precursor cells and is characterized by morphologic and cytomolecular heterogeneity …

Although outcomes of children and adolescents with newly diagnosed acute myeloid
leukemia (AML) have improved significantly over the past two decades, more than one-third …

The incidence of acute myelogenous leukemia (AML) increases progressively with age.
Favorable genetic mutations are most prevalent in children, and unfavorable profiles …

The clinical outcome of acute myeloid leukaemia (AML) in children has improved
considerably using intensive chemotherapy and/or stem cell transplantation. This leads to …

Summary The Medical Research Council Acute Myeloid Leukaemia 12 (MRC AML12) trial
(children) addressed the optimal anthracenedione/anthracycline in induction and the …

Acute myeloid leukemia (AML), a heterogeneous group of diseases with variable responses
to the same therapy, comprises nearly a quarter of childhood acute leukemias. Although …